Clinical Experience of Use of Sacubitril/Valsartan in a Patient with Dilated Cardiomyopathy, Chronic Heart Failure with Reduced Ejection Fraction and Ventricular Arrhythmias

Chronic heart failure is the final stage of the cardiovascular continuum, which is an important cause of disability and reduced life expectancy in developed countries. Optimal medical therapy recommended for patients with symptomatic HF and reduced left ventricular ejection fraction includes angiotensin-converting enzyme inhibitors (or angiotensin II receptor antagonists), beta-blockers and mineralocorticoid receptor antagonists. However, the use of optimal medical therapy does not always lead to the elimination of symptoms, improvement of the quality of life and functional capabilities of patients. Sakubitril/valsartan is a novel combination drug that includes the angiotensin II receptor blocker valsartan and the neprilisin inhibitor sacubitril. In a large PARADIGM-HF clinical trial it demonstrated a 20% reduction in cardiovascular mortality and hospitalization due to decompensation of heart failure compared with standard therapy with enalapril. We report a case of successful use of sacubitril/valsartan in a 61-year-old patient with dilated cardiomyopathy, chronic heart failure with reduced ejection fraction and ventricular arrhythmias. After 6 months of therapy, the patient achieved marked positive dynamics of the clinical status, laboratory and instrumental parameters in absence of any adverse reactions and complications.